Navigation Links
Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market
Date:3/31/2011

NEW YORK, March 31, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market

http://www.reportlinker.com/p0464105/Gout-Therapeutics-Market-to-2017--Entry-of-Novel-Therapies-such-as-Krystexxa-Uloric-Adenuric-and-Colcrys-to-Drive-Market.html

Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market

Summary

GBI Research has released its pharmaceutical research, "Gout Therapeutics Market to 2017 - Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market", which provides insights into gout therapeutics sales and price forecasts until 2017. The report also delves deep into global gout treatment usage patterns. Furthermore, the geographical distribution of the gout therapeutics market across key geographies (the US, the top five countries of Europe, and Japan) is also provided in the report. The report also provides insights into the gout therapeutics R&D pipeline and the promising future blockbusters by 2017. The report provides an in-depth analysis of acute and chronic gout. Furthermore, it also includes the market forecasts and treatment usage patterns of these four therapeutic indications. The report also covers the profiles of major biopharmaceutical companies in this therapeutics segment. Finally, analysis of mergers and acquisitions, and licensing agreements involving gout therapeutics, is also provided.

GBI Research analysis showed that the global gout therapeutics market was estimated at $542.6m in 2010, with a year-on-year growth rate of 7% between 2002 and 2010. The gout therapeutics market is expected to shift towards biologics that are more efficient and safe compared to conventional therapies. GBI Research forecasts the market to grow at a Compound Annual Growth Rate (CAGR) of approximately 16.3% between 2010 and 2017, to record a sales value of approximately $1,561.3m. The gout therapeutics market had only generics until the launch of Colcrys (colchicine) and TMX 67 (febuxostat) in 2009 and 2010 respectively. In-depth analysis of the report is based on proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of experts.

Scope

The report covers -

- Data and analysis on the gout therapeutics market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.

- Annualized market data for the gout therapeutics market from 2002 to 2010, with forecasts to 2017.

- In-depth analysis of the acute and chronic gout therapeutics market.

- Market data on geographical landscape and therapeutic landscape including market size, annual cost of therapy, revenues and treatment usage patterns such as diseased population, treatment seeking population, diagnosed population and prescription population.

- Key drivers and barriers that have created a significant impact on the market.

- Profiles of the major biopharmaceutical markets in the gout therapeutics segment. The key companies studied in this report are Takeda Pharmaceutical Company, Savient Pharmaceuticals, Novartis, Regeneron Pharmaceuticals and Teijin Pharma.

- Key M&A activities and Licensing Agreements, that have taken place between 2004 and 2010 in the gout therapeutics market.

Reasons to buy

The report will aid business development and marketing executives strategizing their product launches -

- Build effective strategies to launch their pipeline products by identifying potential geographies.

- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.

- Develop key strategic initiatives by studying the key strategies of top competitors.

- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.

- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.

Table of Contents

1 Table of Contents

1 Table of Contents 3

1.1 List of Tables 5

1.2 List of Figures 7

2 Gout Therapeutics Market: Introduction 9

2.1 GBI Research Report Guidance 9

3 Gout Therapeutics Market: Market Overview 10

3.1 Introduction 10

3.1.1 Disease Overview 10

3.1.2 Global Market Overview 12

3.2 Revenue Forecasts for the Global Gout Therapeutics Market 12

3.2.1 Revenue 12

3.2.2 Annual Cost of Treatment (ACT) 14

3.2.3 Treatment Usage Patterns 15

4 Gout Therapeutics Market: Geographic Landscape 21

4.1 Revenue Analysis by Geography 21

4.2 The US 23

4.2.1 Revenue 23

4.2.2 Annual Cost of Treatment (ACT) 24

4.2.3 Treatment Usage Patterns 25

4.3 Top Five Countries of Europe 31

4.3.1 Revenue 31

4.3.2 Annual Cost of Treatment (ACT) 32

4.3.3 Treatment Usage Patterns 33

4.3.4 The UK 39

4.3.5 Germany 41

4.3.6 France 43

4.3.7 Italy 45

4.3.8 Spain 47

4.4 Japan 49

4.4.1 Revenue 49

4.4.2 Annual Cost of Treatment (ACT) 50

4.4.3 Treatment Usage Patterns 51

5 Gout Therapeutics Market: Therapeutic Landscape 57

5.1 Gout Therapeutics Market for Acute Gout 57

5.1.1 Introduction 57

5.1.2 Revenue 57

5.1.3 Revenue Analysis by Geography 59

5.1.4 Annual Cost of Treatment 61

5.1.5 Annual Cost of Treatment by Geography 62

5.1.6 Treatment Usage Patterns 64

5.2 Gout Therapeutics Market for Chronic Gout 70

5.2.1 Introduction 70

5.2.2 Revenue 70

5.2.3 Revenue Analysis by Geography 72

5.2.4 Annual Cost of Treatment 74

5.2.5 Annual Cost of Treatment by Geography 75

5.2.6 Treatment Usage Patterns 77

5.3 Drivers and Barriers to the Gout Therapeutics Market 83

5.3.1 Drivers to the Gout Therapeutics Market 83

5.3.2 Barriers to the Gout Therapeutics Market 84

6 Gout Therapeutics Market: Product Pipeline Analysis 85

6.1 Introduction 85

6.2 Research and Development Pipeline 85

6.2.1 Overview 85

6.2.2 Pipeline by Clinical Phases of Development 86

6.3 Profiles of Promising Drugs in the Gout Therapeutics Market 88

6.3.1 ACZ885 88

6.3.2 Arcalyst 88

7 Gout Therapeutics Market: Company Profiles 89

7.1 Takeda Pharmaceutical Company Limited 89

7.1.1 Company Overview 89

7.1.2 SWOT Analysis 89

7.2 Savient Pharmaceuticals, Inc. 90

7.2.1 Company Overview 90

7.2.2 SWOT Analysis 90

7.3 Novartis AG 91

7.3.1 Company Overview 91

7.3.2 SWOT Analysis 91

7.4 Regeneron Pharmaceuticals, Inc. 92

7.4.1 Company Overview 92

7.4.2 SWOT Analysis 92

7.5 Teijin Pharma Limited 93

7.5.1 Company Overview 93

7.5.2 SWOT Analysis 93

8 Gout Therapeutics Market: Strategic Consolidations 94

8.1 Overview 94

8.2 Mergers and Acquisitions 95

8.2.1 Major M&A Deals (2004-2010) 95

8.2.2 Deal Summary 96

8.2.3 Deals by Deal Value 97

8.2.4 Deals by Geography 98

8.2.5 Deals by Type 99

8.3 Licensing Agreements 100

8.3.1 Major Licensing Deals 100

8.3.2 Deal Summary 100

8.3.3 Deals by Geography 102

9 Gout Therapeutics Market: Appendix 103

9.1 Market Definitions 103

9.2 Abbreviations 103

9.3 Research Methodology 104

9.3.1 Coverage 104

9.3.2 Primary Research 105

9.3.3 Forecasts 105

9.3.4 Expert Panel Validation 108

9.4 Contact Us 108

9.5 Disclaimer 108

9.6 Sources 108

List of Tables

1.1 List of Tables

Table 1: Gout Therapeutics Market, Global, Revenue Forecasts, ($m), 2002-2010 13

Table 2: Gout Therapeutics Market, Global, Revenue Forecasts, ($m), 2010-2017 13

Table 3: Gout Therapeutics Market, Global, Annual Cost of Treatment, ($), 2002-2010 14

Table 4: Gout Therapeutics Market, Global, Annual Cost of Treatment, ($), 2010-2017 14

Table 5: Gout Therapeutics Market, Global Treatment Usage Patterns ('000), 2002-2010 15

Table 6: Gout Therapeutics Market, Global Treatment Usage Patterns ('000), 2010-2017 16

Table 7: Gout Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2010 22

Table 8: Gout Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2010-2017 22

Table 9: Gout Therapeutics Market, the US, Revenue Forecasts ($m), 2002-2010 23

Table 10: Gout Therapeutics Market, the US, Revenue Forecasts ($m), 2010-2017 23

Table 11: Gout Therapeutics Market, the US, Annual Cost of Treatment ($), 2002-2010 24

Table 12: Gout Therapeutics Market, the US, Annual Cost of Treatment ($), 2010-2017 24

Table 13: Gout Therapeutics Market, the US, Treatment Usage Patterns ('000), 2002-2010 25

Table 14: Gout Therapeutics Market, the US, Treatment Usage Patterns ('000), 2010-2017 26

Table 15: Gout Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2002-2010 31

Table 16: Gout Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2010-2017 31

Table 17: Gout Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2010 32

Table 18: Gout Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2010-2017 32

Table 19: Gout Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns ('000), 2002-2010 33

Table 20: Gout Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns ('000), 2010-2017 34

Table 21: Gout Therapeutics Market, the UK, Revenue Forecasts, ($m), 2002- 2010 39

Table 22: Gout Therapeutics Market, the UK, Revenue Forecasts, ($m), 2010- 2017 39

Table 23: Gout Therapeutics Market, the UK, Prescription Population ('000), 2002- 2010 40

Table 24: Gout Therapeutics Market, the UK, Prescription Population ('000), 2010- 2017 40

Table 25: Gout Therapeutics Market, Germany, Revenue Forecasts, ($m), 2002- 2010 41

Table 26: Gout Therapeutics Market, Germany, Revenue Forecasts, ($m), 2010- 2017 41

Table 27: Gout Therapeutics Market, Germany, Prescription Population ('000), 2002- 2010 42

Table 28: Gout Therapeutics Market, Germany, Prescription Population ('000), 2010- 2017 42

Table 29: Gout Therapeutics Market, France, Revenue Forecasts, ($m), 2002-2010 43

Table 30: Gout Therapeutics Market, France, Revenue Forecasts, ($m), 2010-2017 43

Table 31: Gout Therapeutics Market, France, Prescription Population ('000), 2002- 2010 44

Table 32: Gout Therapeutics Market, France, Prescription Population ('000), 2010- 2017 44

Table 33: Gout Therapeutics Market, Italy, Revenue Forecasts, ($m), 2002-2010 45

Table 34: Gout Therapeutics Market, Italy, Revenue Forecasts, ($m), 2010-2017 45

Table 35: Gout Therapeutics Market, Italy, Prescription Population ('000), 2002- 2017 46

Table 36: Gout Therapeutics Market, Italy, Prescription Population ('000), 2010- 2017 46

Table 37: Gout Therapeutics Market, Spain, Revenue Forecasts, ($m), 2002-2010 47

Table 38: Gout Therapeutics Market, Spain, Revenue Forecasts, ($m), 2010-2017 47

Table 39: Gout Therapeutics Market, Spain, Prescription Population ('000), 2002- 2010 48

Table 40: Gout Therapeutics Market, Spain, Prescription Population ('000), 2010- 2017 48

Table 41: Gout Therapeutics Market, Japan, Revenue Forecasts ($m), 2002-2010 49

Table 42: Gout Therapeutics Market, Japan, Revenue Forecasts ($m), 2010-2017 49

Table 43: Gout Therapeutics Market, Japan, Annual Cost of Treatment ($), 2002-2010 50

Table 44: Gout Therapeutics Market, Japan, Annual Cost of Treatment ($), 2010-2017 50

Table 45: Gout Therapeutics Market, Japan, Treatment Usage Patterns ('000), 2002-2010 51

Table 46: Gout Therapeutics Market, Japan, Treatment Usage Patterns ('000), 2010-2017 52

Table 47: Gout Therapeutics Market, Acute Gout, Global Revenue Forecasts ($m), 2002-2010 58

Table 48: Gout Therapeutics Market, Acute Gout, Global Revenue Forecasts ($m), 2010-2017 58

Table 49: Gout Therapeutics Market, Acute Gout, Global Revenue Analysis by Geography ($m), 2002-2010 59

Table 50: Gout Therapeutics Market, Acute Gout, Global Revenue Analysis by Geography ($m), 2010-2017 60

Table 51: Gout Therapeutics Market, Acute Gout, Global Annual Cost of Treatment ($), 2002-2010 61

Table 52: Gout Therapeutics Market, Acute Gout, Global Annual Cost of Treatment ($), 2010-2017 61

Table 53: Gout Therapeutics Market, Acute Gout, Global Annual Cost of Treatment by Geography ($), 2002-2010 62

Table 54: Gout Therapeutics Market, Acute Gout, Global Annual Cost of Treatment by Geography ($), 2010-2017 63

Table 55: Gout Therapeutics Market, Acute Gout, Treatment Usage Patterns ('000), 2002-2010 64

Table 56: Gout Therapeutics Market, Acute Gout, Treatment Usage Patterns ('000), 2010-2017 65

Table 57: Gout Therapeutics Market, Chronic Gout, Global Revenue Forecasts ($m), 2002-2010 71

Table 58: Gout Therapeutics Market, Chronic Gout, Global Revenue Forecasts ($m), 2010-2017 71

Table 59: Gout Therapeutics Market, Chronic Gout, Global Revenue Analysis by Geography ($m), 2002-2010 72

Table 60: Gout Therapeutics Market, Chronic Gout, Global Revenue Analysis by Geography ($m), 2010-2017 73

Table 61: Gout Therapeutics Market, Chronic Gout, Global Annual Cost of Treatment ($), 2002-2010 74

Table 62: Gout Therapeutics Market, Chronic Gout, Global Annual Cost of Treatment ($), 2010-2017 74

Table 63: Gout Therapeutics Market, Chronic Gout, Global Annual Cost of Treatment by Geography ($), 2002-2010 75

Table 64: Gout Therapeutics Market, Chronic Gout, Global Annual Cost of Treatment by Geography ($), 2010-2017 76

Table 65: Gout Therapeutics Market, Chronic Gout, Global Treatment Usage Patterns ('000), 2002-2010 77

Table 66: Gout Therapeutics Market, Chronic Gout, Global Treatment Usage Patterns ('000), 2010-2017 78

Table 67: Gout Therapeutics Market, Global, Number of Discovery Molecules, 2010 86

Table 68: Gout Therapeutics Market, Global, Number of Preclinical Molecules, 2010 86

Table 69: Gout Therapeutics Market, Global, Number of IND Filed Molecules, 2010 86

Table 70: Gout Therapeutics Market, Global, Number of Phase I Molecules, 2010 86

Table 71: Gout Therapeutics Market, Global, Number of Phase II Molecules, 2010 87

Table 72: Gout Therapeutics Market, Global, Number of Phase III Molecules, 2010 87

Table 73: Gout Therapeutics Market, Global, Major M&A Deals, 2004-2010 95

Table 74: Gout Therapeutics Market, Global, Major Licensing Deals, 2005-2011 100

List of Figures

1.2 List of Figures

Figure 1: Gout Therapeutics Market, Global, Revenue Forecasts, ($m), 2002-2017 12

Figure 2: Gout Therapeutics Market, Global, Annual Cost of Treatment, ($), 2002-2017 14

Figure 3: Gout Therapeutics Market, Global Treatment Usage Patterns ('000), 2002-2017 15

Figure 4: Gout Therapeutics Market, Global, Diseased Population ('000), 2002-2017 17

Figure 5: Gout Therapeutics Market, Global, Treatment Seeking Population ('000) 18

Figure 6: Gout Therapeutics Market, Global, Diagnosed Population ('000) 19

Figure 7: Gout Therapeutics Market, Global, Prescription Population ('000) 20

Figure 8: Gout Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2017 21

Figure 9: Gout Therapeutics Market, the US, Revenue Forecasts ($m), 2002-2017 23

Figure 10: Gout Therapeutics Market, the US, Annual Cost of Treatment ($), 2002-2017 24

Figure 11: Gout Therapeutics Market, the US, Treatment Usage Patterns ('000), 2002-2017 25

Figure 12: Gout Therapeutics Market, the US, Diseased Population ('000), 2002-2017 27

Figure 13: Gout Therapeutics Market, the US, Treatment Seeking Population ('000), 2002-2017 28

Figure 14: Gout Therapeutics Market, the US, Diagnosed Population ('000), 2002-2017 29

Figure 15: Gout Therapeutics Market, the US, Prescription Population ('000), 2002-2017 30

Figure 16: Gout Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2002-2017 31

Figure 17: Gout Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2017 32

Figure 18: Gout Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns ('000), 2002-2017 33

Figure 19: Gout Therapeutics Market, Top Five Countries of Europe, Diseased Population ('000), 2002-2017 35

Figure 20: Gout Therapeutics Market, Top Five Countries of Europe, Treatment Seeking Population ('000), 2002-2017 36

Figure 21: Gout Therapeutics Market, Top Five Countries of Europe, Diagnosed Population ('000), 2002-2017 37

Figure 22: Gout Therapeutics Market, Top Five Countries of Europe, Prescription Population ('000), 2002-2017 38

Figure 23: Gout Therapeutics Market, the UK, Revenue Forecasts, ($m), 2002-2017 39

Figure 24: Gout Therapeutics Market, the UK, Prescription Population ('000), 2002-2017 40

Figure 25: Gout Therapeutics Market, Germany, Revenue Forecasts, ($m), 2002-2017 41

Figure 26: Gout Therapeutics Market, Germany, Prescription Population ('000), 2002-2017 42

Figure 27: Gout Therapeutics Market, France, Revenue Forecasts, ($m), 2002-2017 43

Figure 28: Gout Therapeutics Market, France, Prescription Population ('000), 2002-2017 44

Figure 29: Gout Therapeutics Market, Italy, Revenue Forecasts, ($m), 2002-2017 45

Figure 30: Gout Therapeutics Market, Italy, Prescription Population ('000), 2002- 2017 46

Figure 31: Gout Therapeutics Market, Spain, Revenue Forecasts, ($m), 2002-2017 47

Figure 32: Gout Therapeutics Market, Spain, Prescription Population ('000), 2002-2017 48

Figure 33: Gout Therapeutics Market, Japan, Revenue Forecasts ($m), 2002-2017 49

Figure 34: Gout Therapeutics Market, Japan, Annual Cost of Treatment ($), 2002-2017 50

Figure 35: Gout Therapeutics Market, Japan, Treatment Usage Patterns ('000), 2002-2017 51

Figure 36: Gout Therapeutics Market, Japan, Diseased Population ('000), 2002-2017 53

Figure 37: Gout Therapeutics Market, Japan, Treatment Seeking Population ('000), 2002-2017 54

Figure 38: Gout Therapeutics Market, Japan, Diagnosed Population ('000), 2002-2017 55

Figure 39: Gout Therapeutics Market, Japan, Prescription Population ('000), 2002-2017 56

Figure 40: Gout Therapeutics Market, Acute Gout, Global Revenue Forecasts ($m), 2002-2017 57

Figure 41: Gout Therapeutics Market, Acute Gout, Global Revenue Analysis by Geography ($m), 2002-2017 59

Figure 42: Gout Therapeutics Market, Acute Gout, Global Annual Cost of Treatment ($), 2002-2017 61

Figure 43: Gout Therapeutics Market, Acute Gout, Global Annual Cost of Treatment by Geography ($), 2002-2017 62

Figure 44: Gout Therapeutics Market, Acute Gout, Treatment Usage Patterns ('000), 2002-2017 64

Figure 45: Gout Therapeutics Market, Acute Gout, Diseased Population ('000), 2002-2017 66

Figure 46: Gout Therapeutics Market, Acute Gout, Treatment Seeking Population ('000), 2002-2017 67

Figure 47: Gout Therapeutics Market, Acute Gout, Diagnosed Population ('000), 2002-2017 68

Figure 48: Gout Therapeutics Market, Acute Gout, Prescription Population ('000), 2002-2017 69

Figure 49: Gout Therapeutics Market, Chronic Gout, Global Revenue Forecasts ($m), 2002-2017 70

Figure 50: Gout Therapeutics Market, Chronic Gout, Global Revenue Analysis by Geography ($m), 2002-2017 72

Figure 51: Gout Therapeutics Market, Chronic Gout, Global Annual Cost of Treatment ($), 2002-2017 74

Figure 52: Gout Therapeutics Market, Chronic Gout, Global Annual Cost of Treatment by Geography ($), 2002-2017 75

Figure 53: Gout Therapeutics Market, Chronic Gout, Global Treatment Usage Patterns ('000), 2002-2017 77

Figure 54: Gout Therapeutics Market, Chronic Gout, Global Diseased Population ('000), 2002-2017 79

Figure 55: Gout Therapeutics Market, Chronic Gout, Global Treatment Seeking Population ('000), 2002-2017 80

Figure 56: Gout Therapeutics Market, Chronic Gout, Global Diagnosed Population ('000), 2002-2017 81

Figure 57: Gout Therapeutics Market, Chronic Gout, Global Prescription Population ('000), 2002-2017 82

Figure 58: Gout Therapeutics Market, Global Drivers and Barriers, 2010-2017 84

Figure 59: Gout Therapeutics Market, Global, Number of Molecules by Phases (%), 2010 85

Figure 60: Gout Therapeutics Market, SWOT Analysis of Takeda Pharmaceutical Company Limited 89

Figure 61: Gout Therapeutics Market, SWOT Analysis of Savient Pharmaceuticals, Inc. 90

Figure 62: Gout Therapeutics Market, SWOT Analysis of Novartis AG 91

Figure 63: Gout Therapeutics Market, SWOT Analysis of Regeneron Pharmaceuticals, Inc. 92

Figure 64: Gout Therapeutics Market, SWOT Analysis of Teijin Pharma Limited 93

Figure 65: Gout Therapeutics Market, Global, Strategic Consolidations, (%), 2004-2010 94

Figure 66: Gout Therapeutics Market, Global, M&A Deals by Value, ($m) 2004-2010 97

Figure 67: Gout Therapeutics Market, Global, M&A Deals by Geography, 2004-2010 98

Figure 68: Gout Therapeutics Market, Global, M&A Deals by Type, 2004-2010 99

Figure 69: Gout Therapeutics Market, Global, Licensing Deals by Geography, 2005-2011 102

Figure 70: GBI Research Market Forecasting Model 107

To order this report:

: Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Contact:
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Reportlinker Adds Top 200 Biopharmaceuticals Industry Report (Global)
2. Reportlinker Adds Butadiene Market In Americas To 2020 - Recovery In End Use Markets Providing Positive Demand Growth In The Region
3. Reportlinker Adds Medical Imaging Markets
4. Reportlinker Adds Cardiac Marker Diagnostic Testing Markets
5. Reportlinker Adds Point of Care Diagnostic Testing World Markets
6. Reportlinker Adds Endoscopy Devices Market to 2016 - Need For Therapeutic Endoscopy and Advancements in HD Endoscopy to Drive Flexible Endoscopes
7. Reportlinker Adds Top 150 Antibiotic Manufacturers (Global)
8. Reportlinker Adds Orthopedics Markets
9. Reportlinker Adds Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
10. Reportlinker Adds Assistive Devices for Special Needs: Technologies and Global Markets
11. Reportlinker Adds Triple Analysis: Colorectal Cancer, Leukemia and Pancreatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... 2016 http://www.researchandmarkets.com/research/fqx6nz/global_skin ) ... Skin Protective Equipment Market 2016-2020" report to ... ) has announced the addition of the ... to their offering. --> ... the addition of the "Global Skin Protective ...
(Date:2/8/2016)... , Feb. 8, 2016  A research team ... scientists has discovered details of how the abnormal breakage ... a particularly aggressive form of acute lymphoblastic leukemia (ALL). ... which genetic mutations trigger overproduction of immature cells, called ... The discoveries of the malfunction underlying the type called ...
(Date:2/8/2016)... -- As part of a major growth and expansion initiative, Dune ... Lori Chmura as President of Dune Inc., its U.S. ... extensive experience in the medical device space will play a ... --> --> In her ... marketing and operational functions in the U.S. She is tasked ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... 08, 2016 , ... Stephanie Hebert Insurance Agency, serving families ... new charity campaign. As part of their ongoing community involvement program, funds are ... that children deserve a voice, and in the spirit of neighbors helping neighbors ...
(Date:2/8/2016)... ... 2016 , ... Tingley Rubber Corporation , a leading ... range of unique and advantaged protective solutions to a growing and dynamic ... customer service and marketing support. A new distribution center in Brampton, Ontario will ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... networking and relationship-marketing firm, announced today that nominations will be accepted February ... (ISE®) West Awards. , Awards include the Information Security Executive® of ...
(Date:2/8/2016)... ... 2016 , ... GrassrootsHealth published data from its D*action public ... in the GrassrootsHealth cohort with substantially higher vitamin D levels than a cohort ... states Carole Baggerly, Director of GrassrootsHealth, “the safety and benefits of vitamin ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... The ... annually in this country. The AutismOne 2016 Conference, which is being held May 25-29 ... often won’t hear elsewhere about helpful interventions and causes of chronic illness in children. ...
Breaking Medicine News(10 mins):